Hoehe MR, Timmermann B, Lehrach H (2003) Human inter-individual DNA sequence variation
in candidate genes, drug targets, the importance of haplotypes and pharmacogenomics. Curr
Pharm Biotechnol 4(6):351–378
Hricak H (2011) Oncologic imaging: a guiding hand of personalized cancer care. Radiology 259
(3):633–640. doi:10.1148/radiol.11110252
Hricak H, Wang L, Wei DC, Coakley FV, Akin O, Reuter VE, Gonen M, Kattan MW, Onyebuchi
CN, Scardino PT (2004) The role of preoperative endorectal magnetic resonance imaging in
the decision regarding whether to preserve or resect neurovascular bundles during radical
retropubic prostatectomy. Cancer 100(12):2655–2663. doi:10.1002/cncr.20319
Jellison BJ, Field AS, Medow J, Lazar M, Salamat MS, Alexander AL (2004) Diffusion tensor
imaging of cerebral white matter: a pictorial review of physics, fiber tract anatomy, and tumor
imaging patterns. AJNR Am J Neuroradiol 25(3):356–369
Kelkar SS, Reineke TM (2011) Theranostics: combining imaging and therapy. Bioconjug Chem
22(10):1879–1903. doi:10.1021/bc200151q
Klayton T, Li T, Yu JQ, Keller L, Cheng J, Cohen SJ, Meropol NJ, Scott W, Xu-Welliver M,
Konski A (2012) The role of qualitative and quantitative analysis of F18-FDG positron
emission tomography in predicting pathologic response following chemoradiotherapy in
patients with esophageal carcinoma. J Gastrointest Cancer 43(4):612–618. doi:10.1007/
s12029-012-9412-3
Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ (2002) PET predicts
prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J
Nucl Med 43(8):1018–1027
Krawczyk N, Banys M, Neubauer H, Solomayer EF, Gall C, Hahn M, Becker S, Bachmann R,
Wallwiener D, Fehm T (2009) HER2 status on persistent disseminated tumor cells after
adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res 29
(10):4019–4024
Lacerda S, Law M (2009) Magnetic resonance perfusion and permeability imaging in brain
tumors. Neuroimaging Clin N Am 19(4):527–557. doi:10.1016/j.nic.2009.08.007
Ludemann L, Warmuth C, Plotkin M, Forschler A, Gutberlet M, Wust P, Amthauer H (2009) Brain
tumor perfusion: comparison of dynamic contrast enhanced magnetic resonance imaging using
T1, T2, and T2* contrast, pulsed arterial spin labeling, and H2(15)O positron emission
tomography. Eur J Radiol 70(3):465–474. doi:10.1016/j.ejrad.2008.02.012
Mozley PD, Schwartz LH, Bendtsen C, Zhao B, Petrick N, Buckler AJ (2010) Change in lung
tumor volume as a biomarker of treatment response: a critical review of the evidence. Ann
Oncol 21(9):1751–1755. doi:10.1093/annonc/mdq051
Nevins JR, Huang ES, Dressman H, Pittman J, Huang AT, West M (2003) Towards integrated
clinico-genomic models for personalized medicine: combining gene expression signatures and
clinical factors in breast cancer outcomes prediction. Hum Mol Genet 12 Spec No 2:R153–
R157. doi:10.1093/hmg/ddg287
Nicolaidis S (2013) Personalized medicine in neurosurgery. Metabolism 62(Suppl 1):S45–S48.
doi:10.1016/j.metabol.2012.08.022
Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, Becker A, Adam M,
Molls M, Dunst J, Terris DJ, Overgaard J (2005) Prognostic value of tumor oxygenation in
397 head and neck tumors after primary radiation therapy. An international multi-center study.
Radiother Oncol 77(1):18–24. doi:10.1016/j.radonc.2005.06.038
Pillai JJ (2010) The evolution of clinical functional imaging during the past 2 decades and its
current impact on neurosurgical planning. AJNR Am J Neuroradiol 31(2):219–225. doi:10.
3174/ajnr.A1845
Rumboldt Z, Al-Okaili R, Deveikis JP (2005) Perfusion CT for head and neck tumors: pilot study.
AJNR Am J Neuroradiol 26(5):1178–1185
Santinelli A, Pisa E, Stramazzotti D, Fabris G (2008) HER-2 status discrepancy between primary
breast cancer and metastatic sites. Impact on target therapy. Int J Cancer 122(5):999–1004.
doi:10.1002/ijc.23051
The Role of Radiology in Personalized Medicine 229